Announcement on Serious Abnormal Fluctuations in Stock Trading
Filed with SSE · · 3 pages · Chinese
BrightGene Bio-Medical Technology Co. Ltd. on 6ix
Earlier from BrightGene Bio-Medical Technology
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Clinical Trials of BGM0504 Tablets
- Announcement on Not Redeeming "BrightGene Convertible Bonds" in Advance
- Indicative Announcement on "Brightgene Convertible Bonds" Expected to Meet Conditions for Redemption
- Report on Use of Previously Raised Funds (2nd Revised Edition)
- BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes and Preclinical Data for Novel Amylin Analog at American Diabetes Association's 85th Scientific Sessions
Later from BrightGene Bio-Medical Technology
- Announcement on the Chairman's Proposal to Repurchase Shares
- Announcement on Increasing of Independent Directors of the 4th Board of Directors and Adjustment of Members of Special Committees of the Board of Directors
- Announcement on Voluntary Disclosure of BGM1812 Injection Obtaining US. FDA Approval for Drug Clinical Trial
- Announcement on Conversion Result of Convertible Bonds and Share Changes
- Announcement on Resolutions of the 11th Meeting of the 4th Board of Supervisors
Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.
Follow BrightGene Bio-Medical Technology